Humalog and Hyperbilirubinaemia aggravated - a phase IV clinical study of FDA data

Summary:

Hyperbilirubinaemia aggravated is found among people who take Humalog, especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months.

The phase IV clinical study analyzes which people take Humalog and have Hyperbilirubinaemia aggravated. It is created by eHealthMe based on reports of 125,852 people who have side effects when taking Humalog from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 28, 2023

125,852 people reported to have side effects when taking Humalog.
Among them, 32 people (0.03%) have Hyperbilirubinaemia aggravated.

What is Humalog?

Humalog has active ingredients of insulin lispro recombinant. It is often used in diabetes. eHealthMe is studying from 126,436 Humalog users for its effectiveness, alternative drugs and more.

What is Hyperbilirubinaemia aggravated?

Hyperbilirubinaemia aggravated (excess of bilirubin in the blood) is found to be associated with 971 drugs and 286 conditions by eHealthMe.

Number of Humalog and Hyperbilirubinaemia aggravated reports submitted per year:

Could Humalog cause Hyperbilirubinaemia aggravated?

Time on Humalog when people have Hyperbilirubinaemia aggravated *:

Gender of people who have Hyperbilirubinaemia aggravated when taking Humalog *:

female: 40.74 %
male: 59.26 %

Age of people who have Hyperbilirubinaemia aggravated when taking Humalog *:

Common drugs people take besides Humalog *:

Common side effects people have besides Hyperbilirubinaemia aggravated *:

Jaundice - Yellow Skin (a yellowish pigmentation of the skin): 8 people, 25.00%
Cholecystitis (infection of gallbladder): 7 people, 21.88%
Nausea (feeling of having an urge to vomit): 5 people, 15.62%
Hyperglycemia (high blood sugar): 5 people, 15.62%
Nausea And Vomiting: 5 people, 15.62%
Foetal Exposure During Pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect): 5 people, 15.62%
Premature Baby: 5 people, 15.62%
Stress And Anxiety: 5 people, 15.62%
Inflammation: 4 people, 12.50%
Irritability: 4 people, 12.50%

Common conditions people have *:

Gestational Diabetes (diabetes in pregnancy): 4 people, 12.50%
High Blood Pressure: 4 people, 12.50%
Hepatitis C: 3 people, 9.38%
Pain: 3 people, 9.38%
Back Pain: 3 people, 9.38%
Depression: 3 people, 9.38%
Abdominal Pain: 3 people, 9.38%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 6.25%
Lung Cancer Metastatic (lung cancer spreads to other parts): 2 people, 6.25%
Breakthrough Pain: 2 people, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Humalog and have Hyperbilirubinaemia aggravated?

Check whether Hyperbilirubinaemia aggravated is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Hyperbilirubinaemia aggravated and when was it recovered:

Hyperbilirubinaemia aggravated in Humalog

Expand to all the drugs that have ingredients of insulin lispro recombinant:

Hyperbilirubinaemia aggravated and drugs with ingredients of insulin lispro recombinant

Alternative drugs to, pros and cons of Humalog:

Humalog (126,436 reports)

Common Humalog side effects:

Browse all side effects of Humalog:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Hyperbilirubinaemia aggravated treatments and more:

Hyperbilirubinaemia aggravated (17 reports)

COVID vaccines that are related to Hyperbilirubinaemia aggravated:

Common drugs associated with Hyperbilirubinaemia aggravated:

How the study uses the data?

The study uses data from the FDA. It is based on insulin lispro recombinant (the active ingredients of Humalog) and Humalog (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.